Ellen Kullman News
-
DuPont Co., the biggest producer of titanium dioxide pigment, is considering whether earnings volatility from the whitening chemical mean the business should be sold, Chief Executive Officer Ellen Kullman said.
-
DuPont Co., the largest U.S. chemical maker by market value, forecast wider profit margins for most of its units in the coming years as the company cuts costs and introduces new products ranging from pesticides to television technology.
-
DuPont Co., the largest U.S. chemical company by market value, posted first-quarter earnings that exceeded analysts’ estimates as profit from crop seeds and pesticides hit a record and pigment demand began to recover.
-
DuPont Co. is known for its dominance in chemicals, but since becoming chief executive officer in 2009, Ellen Kullman has pushed the 210-year-old company into unexpected new businesses. Kullman discusses her plans in Bloomberg Businessweek’s Aug. 13 edition.
-
DuPont Co., the largest U.S. chemical maker by market value, said its solar-materials and pigments businesses will be the biggest beneficiaries from a growing Chinese economy.
-
DuPont Co., the world’s biggest producer of titanium-dioxide pigment, is facing slimmer margins as prices in the $16.3 billion market are poised for the first two-year drop in a decade because of oversupply and weak demand.
-
A DuPont Co. shareholder sued company directors and Chief Executive Officer Ellen Kullman, claiming mismanagement of the seed business led to a $1 billion judgment that threatens to wipe out the company’s cash.
-
Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.
-
DuPont Co., the U.S. chemical maker that posted a 10 percent drop in fourth-quarter sales volumes, said demand may not fully recover until the second quarter.
-
Patent dispute settlements including so-called pay-for-delay deals between branded and generic drug companies jumped to 40 in the year ended in September from 28 the previous year, the U.S. Federal Trade Commission said.
|
|
Most Popular on Bloomberg
|
| |